IDRX
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. IDRx is headquartered in Plymouth, Massachusetts and was founded in 2022.
IDRX
Social Links:
Industry:
Biotechnology Life Science Product Research
Founded:
2022-01-01
Address:
Plymouth, Massachusetts, United States
Country:
United States
Website Url:
http://www.idrx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
122 M USD
Current Advisors List
Current Employees Featured
Founder
Investors List
Casdin Capital
Casdin Capital investment in Series A - Idrx
Forge Life Science Partners
Forge Life Science Partners investment in Series A - Idrx
Nextech Invest
Nextech Invest investment in Series A - Idrx
Andreessen Horowitz
Andreessen Horowitz investment in Series A - Idrx
Official Site Inspections
http://www.idrx.com
- Host name: acd89244c803f7181.awsglobalaccelerator.com
- IP address: 75.2.60.5
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Idrx"
Idrx - Crunchbase Company Profile & Funding
Organization. Idrx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with …See details»
IDRx
IDRx’s pipeline programs include small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal …See details»
IDRx Company Profile 2024: Valuation, Funding & Investors
IDRx General Information Description. Developer of oncology-based precision therapies intended to revolutionize the treatment of cancer. The company designs precision combination …See details»
IDRx - LinkedIn
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s ...See details»
IDRx Strengthens Executive Team with Appointments of Tim …
Mar 12, 2024 Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of. PLYMOUTH, Mass., March 12, 2024--IDRx, …See details»
IDRx Company Profile - Office Locations, Competitors, Revenue
IDRx is a clinical-stage biopharmaceutical company focused on drug development. It designs precision combination therapies for cancer treatment including small molecule tyrosine kinase …See details»
IDRx Reports Updated Preliminary Phase 1 Data from Ongoing …
PLYMOUTH, Mass, June 3, 2024 – IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today …See details»
IDRx Launches with $122 Million Series A Financing to …
Aug 2, 2022 PLYMOUTH, Mass.--(BUSINESS WIRE)--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched ...See details»
IDRx, a new biotech startup, raises $122M to develop …
Aug 2, 2022 Dubbed IDRx, the company has raised $122 million to fund its idea, drawing the support of the well-known venture backers Andreessen Horowitz and Casdin Capital. It’s already equipped with two drugs, licensed from Merck …See details»
IDRx Launches with $122 Million Series A Financing to Treat …
Aug 2, 2022 IDRx’s pipeline includes IDRX-42 and IDRX-73, small molecule tyrosine kinase inhibitors acquired through license agreements with Merck KGaA, Darmstadt, Germany, and …See details»
IDRx Announces $120 Million Series B Financing to Advance …
Aug 7, 2024 IDRx’s lead program is IDRX-42, designed to inhibit key genetic drivers and drug-resistant mutations of KIT in GIST. Founded in 2021, IDRx’s leadership team has extensive …See details»
Cancer Combination Therapy Company IDRx Launches with …
Aug 2, 2022 IDRX-42 was also recently granted Orphan Drug designation by the FDA for the treatment of GIST. IDRX-42 and IDRX-73 are both small molecule TKIs designed to inhibit the …See details»
IDRx nabs $122M to address precision medicine 'whack-a-mole'
Aug 2, 2022 The first, IDRX-42, was licensed from Merck KGaA and has since nabbed orphan-drug designation from the FDA. According to the company’s executives, the therapy is slated …See details»
IDRx raises $120m to fund gastric tumour trials for lead TKI therapy
Aug 7, 2024 In 2022, IDRx raised $122m in Series A financing and licensed two TKI inhibitors – IDRX-42 from Merck KGaA, and IDRX-73 from Blueprint Medicines. Image credit: Mr.Boyz / …See details»
IDRx Reports Updated Preliminary Phase 1 Data from Ongoing …
PLYMOUTH, Mass., June 03, 2024--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today …See details»
IDRx Announces $120 Million Series B Financing to Advance …
PLYMOUTH, Mass., August 07, 2024--IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today …See details»
IDRx
Intelligently designed precision therapies to transform cancer careSee details»
IDRX (IDRX) Price Today, News & Live Chart - Forbes
2 days ago IDRX is a groundbreaking stable token that provides stability and trust in decentralized finance. Each IDRX token represents an equivalent amount of Indonesian …See details»
IDRx
IDRx is committed to studying and developing our investigational drug candidates through clinical trials designed to generate adequate safety and efficacy data in a comprehensive fashion that …See details»